May 16th 2017: Synthetic Biologics - Protecting the Gut Microbiome: A Paradigm Shift in Managing GI Disorders |eCard

SIGN-UP NOW! Click to become a The VoiceAmerica Talk Member for Free!

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 16th 2017: Synthetic Biologics - Protecting the Gut Microbiome: A Paradigm Shift in Managing GI Disorders

Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infe

Read more

DOWNLOAD PDF

GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

LISTEN LIVE

EPISODE ON DEMAND

VIEW HOST PAGE

Questions? Comments?
Call In Live! Call-In
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Dr Joseph Sliman MD

Dr. Sliman, MD, MPH, Chief Medical Officer joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and healt

Read more

Share This Episode

Share On Facebook

Share On Twitter

Share On LinkedIn

Share this E-mail

https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 29/04/2024 08:00 29/04/2024 09:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY

Add to Calendar

Email the Host

Connect with VoiceAmerica

Download our mobile apps